乳腺癌肿瘤整形手术后的长期结果:10年随访
该研究前瞻性纳入2004年1月至2016年3月共350例接受肿瘤整形乳房缩小术(Level 2)的乳腺癌患者,评估长期肿瘤学结局。中位随访55个月,5年局部、区域和远处复发累积发生率分别为2.2%、1.1%和12.4%,总体保乳率92%。结论认为肿瘤整形乳房缩小术允许宽切除并获阴性切缘,可作为大肿瘤替代乳房切除术的选择。
要点
- 肿瘤整形乳房缩小术可用于大肿瘤,总体保乳率达92%。
- 中位随访55个月,5年局部复发率2.2%、远处复发率12.4%。
- 切缘受累率12.6%,术后并发症发生率8.9%。
核心结论
- 肿瘤整形乳房缩小术允许宽切除并获得阴性切缘,可作为大癌症替代乳房切除术的选择。
研究设计与样本
- 前瞻性数据库研究,纳入2004年1月至2016年3月共350例接受肿瘤整形乳房缩小术(Level 2技术)的患者。
主要发现
- 组织学亚型:浸润性导管癌219例(62.6%),导管原位癌(DCIS)88例(25.1%),浸润性小叶癌43例(12.3%)。
- 切缘受累率12.6%(浸润性导管癌10.5%,DCIS 14.7%,浸润性小叶癌20.9%);总体保乳率92%(DCIS 87.4%,浸润性癌93.5%)。
- 5年局部、区域和远处复发累积发生率分别为2.2%、1.1%和12.4%。
临床怎么用
- 对于大肿瘤患者,肿瘤整形乳房缩小术可作为乳房切除术的替代选择,实现宽切除和保乳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to evaluate the long-term oncologic outcome after oncoplastic surgery (OPS). BACKGROUND: OPS combines wide tumor excision with reduction mammoplasty techniques thus extending breast conserving surgery to large tumors that might else be proposed a mastectomy. Little data are available about the oncologic results for breast conserving surgery of these larger tumors. METHODS: From January 2004 until March 2016, a total of 350 oncoplastic breast reductions were prospectively entered into a database. Patients were included if their breast reshaping included a reduction mammoplasty with skin excision (Level 2 oncoplastic techniques). RESULTS: Histologic subtypes were: invasive ductal carcinoma in 219 cases (62.6%), ductal carcinoma in situ (DCIS) in 88 cases (25.1%), and invasive lobular carcinoma in 43 (12.3%) cases. Seventy-three of the invasive cancers (27.9%) received neoadjuvant chemotherapy. The mean resection weight was 177 grams. The mean pathological tumor size was 26 mm (range 0-180 mm) and varied from 23 mm (4-180 mm) for invasive cancers to 32 mm (0-100 mm) for DCIS. Specimen margins were involved in 12.6% of the cases; 10.5% of invasive ductal, 14.7% of DCIS, and 20.9% of invasive lobular. The overall breast conservation rate was 92% and varied from 87.4% for DCIS to 93.5% for the invasive cancers. Thirty-one patients (8.9%) developed one or more postoperative complications, inducing a delay in postoperative treatments in 4.6% of patients. The median follow up was 55 months. The cumulative 5-year incidences for local, regional, and distant recurrences were 2.2%, 1.1%, and 12.4%, respectively. CONCLUSIONS: Oncoplastic breast reductions allow wide resections with free margins and can be used for large cancers as an alternative to mastectomy.
引用
- Clough KB, van la Parra RFD, Thygesen HH, et al. Long-term Results After Oncoplastic Surgery for Breast Cancer: A 10-year Follow-up. Ann Surg. 2018. PMID: 28448389. doi:10.1097/SLA.0000000000002255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。